Peapack Gladstone Financial Corp Biomarin Pharmaceutical Inc Transaction History

Peapack Gladstone Financial Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$82.16 - $96.94 $12,324 - $14,541	-150 Reduced 5.45%	2,600 $220,000
Q2 2022 Aug 12, 2022	SELL	$71.48 - $86.85 $167,978 - $204,097	-2,350 Reduced 46.08%	2,750 $228,000
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $14,856 - $18,538	-200 Reduced 3.77%	5,100 $393,000
Q4 2021 Feb 15, 2022	BUY	$71.72 - $91.47 $19,364 - $24,696	270 Added 5.37%	5,300 $468,000
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $85,985 - $98,290	1,150 Added 29.64%	5,030 $388,000
Q2 2021 Aug 16, 2021	BUY	$75.51 - $84.79 $45,306 - $50,874	600 Added 18.29%	3,880 $324,000
Q1 2021 May 14, 2021	BUY	$74.73 - $90.69 $245,114 - $297,463	3,280 New	3,280 $247,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Peapack Gladstone Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Peapack Gladstone Financial Corp with notifications on news.